Tonix Pharma (TNXP) Issues Positive Update from End-of-Phase 2/Pre-Phase 3 FDA Meeting for TNX-102 SL in PTSD

Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder

Regulatory Acceptance of Phase 3 Program and Product Registration Plan

Dosing in First Phase 3 Trial Expected to Commence in the First Quarter of 2017

NEW YORK, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder... More